Theratechnologies VE/BAIIA
Quel est le VE/BAIIA de Theratechnologies?
Le VE/BAIIA de Theratechnologies, Inc. est N/A
Quelle est la définition de VE/BAIIA?
VE/BAIIA est la valeur de l’entreprise divisée par le bénéfice avant intérêts, impôts, dépréciations et amortissements. Il s'agit d'une mesure du coût d'une action et est plus souvent valable pour des comparaisons entre sociétés que le ratio cours / bénéfice. Il mesure le prix (sous forme de valeur d'entreprise) qu'un investisseur paie au profit des flux de trésorerie de l'entreprise (sous forme de BAIIA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
VE/BAIIA des entreprises dans Health Care secteur sur TSX par rapport à Theratechnologies
Que fait Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Entreprises avec ve/baiia similaire à Theratechnologies
- Avira Resources a VE/BAIIA de N/A
- Avalon GloboCare a VE/BAIIA de N/A
- Westport Fuel Systems a VE/BAIIA de N/A
- Sequana Medical NV a VE/BAIIA de N/A
- Mint Payments a VE/BAIIA de N/A
- FRX Innovations a VE/BAIIA de N/A
- Theratechnologies a VE/BAIIA de N/A
- Bubblr Inc a VE/BAIIA de N/A
- Mithra Pharmaceuticals SA a VE/BAIIA de N/A
- Auxly Cannabis a VE/BAIIA de N/A
- Spey Resources Corp a VE/BAIIA de N/A
- Golden Deeps a VE/BAIIA de N/A
- Red Lion Hotels a VE/BAIIA de N/A